Protocol Ledger

NCT06927310 · Phase III · RECRUITING

The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature

Interventional Phase III clinical trial protocol NCT06927310 sponsored by Xiamen Amoytop Biotech Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-04-28 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06927310
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06927310
Protocol FieldVerified Registry Value
NCT IdentifierNCT06927310
Consolidated Lead SponsorXiamen Amoytop Biotech Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2025-04-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI